Back to search
FDAFDA · Food and drugs·Recall number D-0898-2017

Levophed norepinephrine bitartrate, injection, USP, 4 mg /4 mL (1 mg/mL),Rx only, Hospira, Inc. Lake Forest, IL --- NDC 0409-3375-04

Published June 21, 2017 · Recall initiated: May 18, 2017

Summary

FDA records drug Class II recall D-0898-2017, published June 21, 2017 and initiated May 18, 2017. Recalling firm: Hospira Inc., A Pfizer Company; Status: Terminated; Reported quantity: (720503A): 43,200 vials, (720603A): 400 vials; Lot: 720503A, 720603A (Canada only). Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

GMP Deviation; A foreign stopper was observed during packaging of a lot of product.

What to do

Voluntary: Firm initiated · Letter

Get an email if LEVOPHED has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
LEVOPHED
Manufacturer
Hospira Inc., A Pfizer Company
Distributor
Nationwide, Canada and Singapore
Lot
720503A, 720603A (Canada only)
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Levophed norepinephrine bitartrate, injection, USP, 4 mg /4 mL (1 mg/mL),Rx only, Hospira, Inc. Lake Forest, IL --- NDC 0409-3375-04 recalled?

Yes. FDA published recall D-0898-2017 on June 21, 2017. Reported hazard: GMP Deviation; A foreign stopper was observed during packaging of a lot of product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: LEVOPHED.